Dupilumab, an IL-4 receptor α inhibitor that blocks the activity of both IL-4 and IL-13, was the first non-traditional immunomodulator agent approved for the treatment of moderate-to-severe AD in patients with 6 years of age or older. This evidence concerns the gene IL4 and Alzheimer disease.